JP2021535213A - ＡｈＲモジュレーターとしてのテトラヒドロピリドピリミジン誘導体 - Google Patents

ＡｈＲモジュレーターとしてのテトラヒドロピリドピリミジン誘導体 Download PDF

Info

Publication number
JP2021535213A
JP2021535213A JP2021534826A JP2021534826A JP2021535213A JP 2021535213 A JP2021535213 A JP 2021535213A JP 2021534826 A JP2021534826 A JP 2021534826A JP 2021534826 A JP2021534826 A JP 2021534826A JP 2021535213 A JP2021535213 A JP 2021535213A
Authority
JP
Japan
Prior art keywords
minutes
pyrimidine
ethyl
indole
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021534826A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535213A5 (https=
JPWO2020039093A5 (https=
Inventor
メテ，アントニオ
ヒッチン，ジェームズ，アール
グラハム，マーク
キング−アンダーウッド，ジョン
ソーン，フィリップ，ヴェラコット
Original Assignee
ジャガー セラピューティクス ピーティーイーリミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジャガー セラピューティクス ピーティーイーリミテッド filed Critical ジャガー セラピューティクス ピーティーイーリミテッド
Publication of JP2021535213A publication Critical patent/JP2021535213A/ja
Publication of JP2021535213A5 publication Critical patent/JP2021535213A5/ja
Publication of JPWO2020039093A5 publication Critical patent/JPWO2020039093A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021534826A 2018-08-24 2019-08-23 ＡｈＲモジュレーターとしてのテトラヒドロピリドピリミジン誘導体 Pending JP2021535213A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201807244X 2018-08-24
SG10201807244X 2018-08-24
PCT/EP2019/072641 WO2020039093A1 (en) 2018-08-24 2019-08-23 Tetrahydropyridopyrimidine derivatives as ahr modulators

Publications (3)

Publication Number Publication Date
JP2021535213A true JP2021535213A (ja) 2021-12-16
JP2021535213A5 JP2021535213A5 (https=) 2022-08-30
JPWO2020039093A5 JPWO2020039093A5 (https=) 2022-08-30

Family

ID=67982013

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021534826A Pending JP2021535213A (ja) 2018-08-24 2019-08-23 ＡｈＲモジュレーターとしてのテトラヒドロピリドピリミジン誘導体

Country Status (14)

Country Link
US (1) US12221439B2 (https=)
EP (1) EP3841102B1 (https=)
JP (1) JP2021535213A (https=)
KR (1) KR20210049135A (https=)
CN (1) CN112739698A (https=)
AU (1) AU2019323714A1 (https=)
BR (1) BR112021003529A2 (https=)
CA (1) CA3110402A1 (https=)
IL (1) IL281023A (https=)
MX (1) MX2021002215A (https=)
PH (1) PH12021550382A1 (https=)
SG (1) SG11202101441SA (https=)
WO (1) WO2020039093A1 (https=)
ZA (1) ZA202100931B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3715471A1 (en) 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ahr signature marker set
EP3721894A1 (en) 2019-04-10 2020-10-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof
EP3835432A1 (en) 2019-12-10 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer
US20230279000A1 (en) 2020-02-26 2023-09-07 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of ahr signalling
WO2021210970A1 (en) * 2020-04-17 2021-10-21 Dong-A St Co., Ltd. Pyridopyrimidinone derivatives and their use as aryl hydrocarbon receptor modulators
WO2022078356A1 (zh) * 2020-10-15 2022-04-21 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
WO2023033742A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
WO2023033741A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
WO2024076300A1 (en) 2022-10-03 2024-04-11 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044762A2 (en) * 2004-10-15 2006-04-27 Bayer Pharmaceuticals Corporation Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor
JP2007501258A (ja) * 2003-08-05 2007-01-25 バーテックス　ファーマシューティカルズ　インコーポレイテッド 電位依存型イオンチャネルの阻害剤としての縮合ピリミジン化合物
JP2012507554A (ja) * 2008-10-30 2012-03-29 アイアールエム・リミテッド・ライアビリティ・カンパニー 造血幹細胞を増加させる化合物
US20120136012A1 (en) * 2009-08-17 2012-05-31 Merck Sharp & Dohme Corp Amino tetrahydro-pyridopyrimidine pde10 inhibitors
WO2016154110A1 (en) * 2015-03-20 2016-09-29 Cleave Biosciences, Inc. Companion diagnostic for p97 inhibitor therapy and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
EP1317450B1 (en) 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MY159230A (en) 2008-10-02 2016-12-30 Respivert Ltd P38 map kinase inhibitors
BR112013002079B1 (pt) 2010-07-27 2021-09-14 Trustees Of Boston University Modificadores do receptor de aril hidrocarboneto (ahr) como novos terapêuticos contra o câncer
CA3025227A1 (en) 2016-05-25 2017-11-30 Bayer Pharma Aktiengesellschaft 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
US20230279000A1 (en) 2020-02-26 2023-09-07 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of ahr signalling

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007501258A (ja) * 2003-08-05 2007-01-25 バーテックス　ファーマシューティカルズ　インコーポレイテッド 電位依存型イオンチャネルの阻害剤としての縮合ピリミジン化合物
WO2006044762A2 (en) * 2004-10-15 2006-04-27 Bayer Pharmaceuticals Corporation Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor
JP2012507554A (ja) * 2008-10-30 2012-03-29 アイアールエム・リミテッド・ライアビリティ・カンパニー 造血幹細胞を増加させる化合物
US20120136012A1 (en) * 2009-08-17 2012-05-31 Merck Sharp & Dohme Corp Amino tetrahydro-pyridopyrimidine pde10 inhibitors
WO2016154110A1 (en) * 2015-03-20 2016-09-29 Cleave Biosciences, Inc. Companion diagnostic for p97 inhibitor therapy and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY, JPN7023002854, 2011, ISSN: 0005282688 *
DATABASE REGISTRY, JPN7023002855, 2012, ISSN: 0005282687 *

Also Published As

Publication number Publication date
CA3110402A1 (en) 2020-02-27
WO2020039093A1 (en) 2020-02-27
EP3841102A1 (en) 2021-06-30
US20210332041A1 (en) 2021-10-28
IL281023A (en) 2021-04-29
ZA202100931B (en) 2021-10-27
EP3841102B1 (en) 2022-09-14
MX2021002215A (es) 2021-07-15
CN112739698A (zh) 2021-04-30
KR20210049135A (ko) 2021-05-04
BR112021003529A2 (pt) 2021-05-18
AU2019323714A1 (en) 2021-03-25
US12221439B2 (en) 2025-02-11
PH12021550382A1 (en) 2021-12-13
SG11202101441SA (en) 2021-03-30

Similar Documents

Publication Publication Date Title
US12221439B2 (en) Tetrahydropyridopyrimidine derivatives as AhR modulators
JP6564406B2 (ja) カゼインキナーゼ１デルタ／イプシロン阻害剤としてのイミダゾ−ピリダジン誘導体
JP2018150358A (ja) Ｔａｎｋ結合キナーゼインヒビター化合物
JP2023506147A (ja) Ｍｅｔｔｌ３阻害剤としてのポリヘテロ環式化合物
BR112016016289B1 (pt) Heteroaris e usos dos mesmos
WO2020021024A1 (en) Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
US20250215013A1 (en) Substituted tricyclic compounds as parp inhibitors and the use thereof
US12202816B2 (en) Compounds as NADPH oxidase inhibitors
AU2024321427A1 (en) Pharmaceutical compounds and compositions as c-kit kinase inhibitors
JP2022512536A (ja) 癌を治療するために有用なＥｒｂＢ調節剤としての４－置換ピロロ［２，３－ｂ］ピリジン
WO2025019309A2 (en) Compounds and compositions as c-kit kinase inhibitors
WO2025024503A1 (en) PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS
AU2019363657B2 (en) 5-azaindazole derivatives as adenosine receptor antagonists
KR20220153595A (ko) AhR 신호전달의 조절에 유용한 피리도피리미딘 유도체
CN115433211A (zh) 吡嗪并吡啶酮类蛋氨酸腺苷转移酶2a抑制剂
HK40055989A (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
HK40055989B (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
EP4396191B1 (en) Compounds useful in modulation of ahr signalling
KR20250073623A (ko) AhR 신호전달의 조절에 유용한 화합물
WO2023033742A1 (en) Compounds useful in modulation of ahr signalling
WO2025234404A1 (ja) ピリミジン含有縮合環化合物及びその用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220822

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220822

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240313

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241002